Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:22:50 EDT Wed 15 Jul 2026
Enter Symbol
or Name
USA
CA



Q:ATOS - ATOSSA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATOS - Q0.22.18·2.800.82.44+0.188.097.12027862.29  2.44  2.226219.35  1.7019:41:18Jun 1215 min RT 2¢

Recent Trades - Last 10 of 786
Time ETExPriceChangeVolume
19:41:18Q2.460.207
19:41:18Q2.460.204
19:05:23Q2.460.206
18:42:19Q2.460.202
18:40:01Q2.450.199
18:40:01Q2.460.201
18:39:11Q2.450.192
18:39:11Q2.450.191
18:39:05Q2.450.1910
18:39:05Q2.450.198

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-06-12 17:30U:ATOSNews ReleaseAtossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
2026-06-11 08:00U:ATOSNews ReleaseAtossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
2026-05-27 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
2026-05-20 16:45U:ATOSNews ReleaseAtossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
2026-05-14 08:30U:ATOSNews ReleaseAtossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
2026-05-08 08:45U:ATOSNews ReleaseAtossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2026-05-06 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
2026-05-04 08:30U:ATOSNews ReleaseAtossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
2026-03-25 17:30U:ATOSNews ReleaseAtossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
2026-03-19 11:00U:ATOSNews ReleaseThe Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
2026-03-19 08:00U:ATOSNews ReleaseAtossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
2026-03-12 08:00U:ATOSNews ReleaseAtossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
2026-02-11 08:30U:ATOSNews ReleaseAtossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
2026-02-05 08:30U:ATOSNews ReleaseAtossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
2026-01-21 09:05U:ATOSNews ReleaseAtossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
2026-01-16 16:40U:ATOSNews ReleaseAtossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
2026-01-06 08:15U:ATOSNews ReleaseAtossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
2025-12-17 08:15U:ATOSNews ReleaseAtossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
2025-12-15 08:00U:ATOSNews ReleaseAtossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
2025-12-11 08:00U:ATOSNews ReleaseAtossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy